JPMorgan lowered the firm’s price target on Edwards Lifesciences to $84 from $100 and keeps an Overweight rating on the shares. The company reported in-line Q3 results but guidance for the full-year was lowered to the lower half of previous ranges on both the top and bottom, the analyst tells investors in a research note. The firm says that with Q4 guidance pointing towards performance slightly below previous expectations as TAVR expectations have moved down, it isn’t surprised to see shares indicated down.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
- Edwards Lifesciences backs FY23 adjusted EPS $2.50-$2.60, consensus $2.55
- Edwards Lifesciences sees Q4 adjusted EPS 60c-66c, consensus 68c
- Edwards Lifesciences reports Q3 adjusted EPS 59c, consensus 59c
- Edwards Lifesciences options imply 6.8% move in share price post-earnings